Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $43.09 · 11 analysts
Stored first · Google News · Yahoo Finance (English)
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10 - Seeking Alpha
Immunic, Inc. (IMUX) Presents at EFMC Medicinal Chemistry 2026 Basel - Slideshow (NASDAQ:IMUX) 2026-09-10 Seeking Alpha
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 - GuruFocus
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 GuruFocus
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? - Kalkine Media
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? Kalkine Media
Stifel reiterates Immunic stock rating on MS drug potential - Investing.com
Stifel reiterates Immunic stock rating on MS drug potential Investing.com
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com Investing.com Canada
Immunic to host virtual relapsing MS R&D Day on September 9
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-1.18 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 22. | B. Riley Securities | — | Maintain | Buy → Buy | — | B. Riley Securities: Buy |
| 2026. 04. 30. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2026. 04. 17. | Stifel | — | Initiate coverage | — → Buy | — | Stifel: Buy |
| 2026. 04. 15. | D. Boral Capital | — | Downgrade | Buy → Hold | — | D. Boral Capital: Buy → Hold |
| 2026. 03. 24. | Guggenheim | — | Initiate coverage | — → Buy | — | Guggenheim: Buy |
| 2026. 03. 02. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 67,186 | $74.58K | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 76,186 | $40.66K | 0.00% | — | New position |
